Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Triple Negative Breast Cancer Malignancies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT03992131
What this trial is testing

Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

Who this might be right for
Ovarian CancerTriple-negative Breast CancerUrothelial Carcinoma+1 more
pharmaand GmbH 25
Early research (Phase 1)Looking for participantsNCT02926690
What this trial is testing

Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

Who this might be right for
Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer
OncoTherapy Science, Inc. 70
Testing effectiveness (Phase 2)Looking for participantsNCT05076682
What this trial is testing

Reverse Triple Negative Immune Resistant Breast Cancer

Who this might be right for
Triple-negative Breast Cancer
Fudan University 80
Testing effectiveness (Phase 2)UnknownNCT04676997
What this trial is testing

Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)

Who this might be right for
Triple Negative Breast Cancer
Shandong Cancer Hospital and Institute 20
Testing effectiveness (Phase 2)Study completedNCT02460224
What this trial is testing

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Who this might be right for
Advanced Solid Tumors
Novartis Pharmaceuticals 490
Not applicableStudy completedNCT05111067
What this trial is testing

Molecular Subtyping of Triple-negative Breast Cancer and African Ancestry-related Immunogenicity

Who this might be right for
Triple Negative Breast Cancer
Nova Scotia Health Authority 120
Testing effectiveness (Phase 2)Looking for participantsNCT04771871
What this trial is testing

MicroRNA Profiles in Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
University College Hospital, Ibadan 42
Testing effectiveness (Phase 2)Study completedNCT01672671
What this trial is testing

BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy

Who this might be right for
Early Triple Negative Breast Cancer
Russian Academy of Medical Sciences 41
Not applicableStudy completedNCT05730010
What this trial is testing

Discerning the Impact of ctDNA Detection on Patient Decision Making in Early Stage Breast Cancer: a Conjoint Analysis

Who this might be right for
Triple Negative Breast Cancer
Indiana University 289
Early research (Phase 1)WithdrawnNCT01333423
What this trial is testing

Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Ended earlyNCT00542191
What this trial is testing

Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer

Who this might be right for
Breast Cancer
Leo W. Jenkins Cancer Center 30
Testing effectiveness (Phase 2)Ended earlyNCT03244358
What this trial is testing

Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Sun Yat-sen University 12
Early research (Phase 1)Study completedNCT01969643
What this trial is testing

A Safety Study of SGN-LIV1A in Breast Cancer Patients

Who this might be right for
HER2 Positive Breast NeoplasmsHormone Receptor Positive Breast NeoplasmsTriple Negative Breast Neoplasms+1 more
Seagen Inc. 290
Early research (Phase 1)Looking for participantsNCT06246968
What this trial is testing

Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer

Who this might be right for
Metastatic Breast CancerBreast CancerBreast Cancer Stage IV+5 more
Memorial Sloan Kettering Cancer Center 30
Early research (Phase 1)UnknownNCT04432857
What this trial is testing

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Who this might be right for
Triple-negative Breast CancerNSCLC, Squamous or Non-SquamousUrothelial Carcinoma of the Bladder+2 more
Adlai Nortye Biopharma Co., Ltd. 63
Testing effectiveness (Phase 2)Looking for participantsNCT06682195
What this trial is testing

Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)

Who this might be right for
TNBC, Triple Negative Breast Cancer
First Affiliated Hospital of Zhejiang University 35
Not applicableLooking for participantsNCT07216495
What this trial is testing

Pilot Study of Aerobic Exercise During Immune Checkpoint Inhibitor Therapy in Early-Stage TNBC

Who this might be right for
Aerobic ExerciseEarly Stage Triple Negative Breast Cancer
M.D. Anderson Cancer Center 33
Testing effectiveness (Phase 2)Study completedNCT02648477
What this trial is testing

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Negative+4 more
City of Hope Medical Center 30
Testing effectiveness (Phase 2)Study completedNCT04332653
What this trial is testing

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Who this might be right for
Any Advanced Solid TumorsTriple Negative Breast CancerNon Small Cell Lung Cancer+4 more
NeoImmuneTech 215
Not applicableLooking for participantsNCT06240195
What this trial is testing

Biomarkers of Efficacy and Tolerability of Sacituzumab-Govitecan in the Treatment of Patients With Triple-negative Breast Cancer in the Metastatic Phase: Prospective Multicenter Real-world Study

Who this might be right for
Breast Cancer
Regina Elena Cancer Institute 60
Next Page